Research Peptide, Metabolic Research, All

NL-RETA

Bundle & Save

Single

$110.00

per bottle

—

3+ Bottles

per bottle

5% off

Title	Quantity	Discount
Discount	1 - 3	0% $110.00
Discount	4 - 5	5% $104.50
Discount	6 - 7	8% $101.20
Discount	8 +	10% $99.00

Title	Quantity	Discount
Discount	1 - 3	0% $110.00
Discount	4 - 5	5% $104.50
Discount	6 - 7	8% $101.20
Discount	8 +	10% $99.00

Description

NL-RETA is a retatrutide research analog designed for laboratory investigation of multi-receptor incretin signaling. Retatrutide, also known in published research as LY3437943, is studied as a triple receptor agonist model involving GLP-1, GIP, and glucagon receptor pathways. This multi-pathway profile makes it useful for preclinical research into metabolic regulation, energy balance, glucose signaling, lipid metabolism, and body-composition pathway modeling.

This compound is intended strictly for in vitro and preclinical laboratory research.

Specifications

Product Classification: Research-Use-Only (RUO)
Total Content: 10 mg lyophilized powder per vial
Compound: Retatrutide research analog
Form: Sterile lyophilized peptide compound
Purity: ≥99%
Storage: Store at −20 °C, protected from light
Packaging: Glass vial in protective sleeve

Applications

Intended for preclinical laboratory research only, including:
• GLP-1 receptor signaling models
• GIP receptor pathway research
• Glucagon receptor activity studies
• Multi-receptor incretin pathway analysis
• Energy expenditure and metabolic regulation models
• Glucose and lipid metabolism experiments
• Comparative incretin analog research

Warning

Not for human or animal use. For research purposes only.

Scientific Report

Abstract

Retatrutide is a synthetic multi-receptor agonist investigated for activity at GLP-1, GIP, and glucagon receptors. This triple-pathway profile allows researchers to model combined incretin and glucagon receptor signaling in controlled experimental systems. NL-RETA is designed for laboratory use in studies examining metabolic signaling, receptor selectivity, energy regulation, lipid metabolism, glucose pathway modulation, and downstream cellular responses associated with incretin-receptor activation.

Mechanistic Pathway

NL-RETA is designed around triple incretin and glucagon receptor pathway modeling.

GLP-1 Receptor Pathway

Supports research into incretin signaling
Used in glucose-regulatory pathway models
Studied for effects on downstream metabolic signaling

Effect: Models GLP-1 receptor activity in controlled research systems.

GIP Receptor Pathway

Supports investigation of GIP-associated signaling
Used in models of insulinotropic and metabolic pathway interaction
Helps study receptor cross-talk in incretin systems

Effect: Enables research into GIP pathway contribution to multi-receptor metabolic signaling.

Glucagon Receptor Pathway

Supports research into energy expenditure signaling
Used in lipid metabolism and hepatic pathway models
Helps evaluate the glucagon component of triple-agonist systems

Effect: Provides a model for glucagon receptor contribution to metabolic regulation research.

Pharmacokinetics / Research Profile

Compound	Pathway	Research Notes
Retatrutide analog	GLP-1R / GIPR / GCGR	Triple receptor agonist model for metabolic pathway research

Dosing Models in Research

Used only in controlled in vitro and preclinical research models to study receptor signaling and metabolic pathway response. No human or animal-use instructions are provided.

Preclinical Research Highlights

Studied as a triple agonist model involving GLP-1, GIP, and glucagon receptors
Used in metabolic regulation and energy-balance pathway research
Supports comparative studies with single and dual incretin agonist models
Relevant to glucose signaling, lipid metabolism, and receptor cross-talk studies
Useful for evaluating downstream effects of multi-receptor peptide signaling

Conclusion

NL-RETA offers a research-use-only model for studying triple receptor incretin and glucagon pathway activation. By engaging GLP-1, GIP, and glucagon receptor signaling models, it supports advanced preclinical investigation into metabolic regulation, receptor cross-talk, glucose pathway signaling, lipid metabolism, and energy-balance mechanisms.